Review decision – July 2018
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA345; Naloxegol for treating opioid induced constipation.
No new evidence has been identified that is likely to change the recommendations in TA345.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently TA345 will move to the ‘static list’ of technology appraisals.
This page was last updated: 09 July 2018